At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BK4556 Gene Editing
Trading 04-09 10:07:33 EDT
446.91
+2.22
+0.50%
High448.05Low439.80Vol1.86M
Open443.41D1 Closing444.69Amplitude1.85%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O17.21MT/O Rate--Tradable Shares0.00
P/B2.387151ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Is CRISPR Therapeutics (CRSP) Pricing Reflect Its Sharp Five‑Year Share Price Pullback
Simply Wall St.  ·  19:27
Is CRISPR Therapeutics (CRSP) Pricing Reflect Its Sharp Five‑Year Share Price Pullback
Editas Medicine replaces Ernst & Young with PwC as auditor for 2026
Reuters  ·  04-08 04:29
Editas Medicine replaces Ernst & Young with PwC as auditor for 2026
CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
GlobeNewswire  ·  04-07 20:00
CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Why Beam Therapeutics (BEAM) Is Up 12.6% After NEJM Base-Editing Sickle Cell Data Publication
Simply Wall St.  ·  04-06 23:15
Why Beam Therapeutics (BEAM) Is Up 12.6% After NEJM Base-Editing Sickle Cell Data Publication
Intellia grants 67,150 inducement RSUs to 13 new employees under 2024 plan
Reuters  ·  04-04
Intellia grants 67,150 inducement RSUs to 13 new employees under 2024 plan
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  04-04
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRISPR Therapeutics announces annual shareholder meeting, releases preliminary proxy statement
Reuters  ·  04-03
CRISPR Therapeutics announces annual shareholder meeting, releases preliminary proxy statement
Beam Therapeutics CEO John M. Evans disposes of $1.1 million common shares
Reuters  ·  04-02
Beam Therapeutics CEO John M. Evans disposes of $1.1 million common shares
Beam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial
TIPRANKS  ·  04-02
Beam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial
Beam risto-cel BEACON trial data in NEJM support BLA filing by late 2026
Reuters  ·  04-02
Beam risto-cel BEACON trial data in NEJM support BLA filing by late 2026
Analysts Have Conflicting Sentiments on These Healthcare Companies: Terns Pharmaceuticals (TERN), Sangamo Therapeutics (SGMO) and Galectin Therapeutics (GALT)
TIPRANKS  ·  03-31
Analysts Have Conflicting Sentiments on These Healthcare Companies: Terns Pharmaceuticals (TERN), Sangamo Therapeutics (SGMO) and Galectin Therapeutics (GALT)
Sangamo Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  03-31
Sangamo Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Sangamo reports Q4 EPS (11c), consensus (5c)
TIPRANKS  ·  03-31
Sangamo reports Q4 EPS (11c), consensus (5c)
Sangamo publishes corporate presentation highlighting neurology genomic medicines pipeline, Fabry BLA progress
Reuters  ·  03-31
Sangamo publishes corporate presentation highlighting neurology genomic medicines pipeline, Fabry BLA progress
Sangamo Q4 revenue misses analyst expectations
Reuters  ·  03-31
Sangamo Q4 revenue misses analyst expectations
Sangamo FY25 net loss widens to $123 million; revenue drops to $40 million
Reuters  ·  03-31
Sangamo FY25 net loss widens to $123 million; revenue drops to $40 million
BRIEF-Sangamo Therapeutics Q4 EPS USD -0.11
Reuters  ·  03-31
BRIEF-Sangamo Therapeutics Q4 EPS USD -0.11
Sangamo Therapeutics Q4 Revenue USD 14.228 Million
THOMSON REUTERS  ·  03-31
Sangamo Therapeutics Q4 Revenue USD 14.228 Million
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
THOMSON REUTERS  ·  03-31
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Sangamo options imply 27.2% move in share price post-earnings
TIPRANKS  ·  03-31
Sangamo options imply 27.2% move in share price post-earnings

Introduction

Company Name.
BK4556
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--